Wiborg assists Prophylix Pharma AS get €6 m grant

Consortium led by Prophylix Pharma AS has been granted up to €6 million by EU for the development of a prophylactic treatment of severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia (FNAIT).


Further information about the project and the consortium can be found at the PROFNAIT project web site (www.profnait.eu).

For more information PLEASE click here or to book a meeting already today!
Copyright © 2017 Wiborg ApS. All rights reserved.